These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35642038)

  • 1. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
    Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
    J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
    Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
    BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
    Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
    Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Value of the
    Pan YH; Zhang JX; Chen X; Liu F; Cao JZ; Chen Y; Chen W; Luo JH
    Front Immunol; 2021; 12():643282. PubMed ID: 34421886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
    Front Immunol; 2020; 11():1620. PubMed ID: 32903763
    [No Abstract]   [Full Text] [Related]  

  • 7. PTCH1 mutation as a potential predictive biomarker for immune checkpoint inhibitors in gastrointestinal cancer.
    Deng S; Gu H; Chen Z; Liu Y; Zhang Q; Chen D; Yi S
    Carcinogenesis; 2024 May; 45(5):351-357. PubMed ID: 38310539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.
    Li GX; Chang RZ; Liu TT; Jin GN; Lu K; Yong TY; Li Z; Liu JH; Zhang B; Zhang WG; Ding ZY
    Cancer Gene Ther; 2024 Apr; 31(4):586-598. PubMed ID: 38267623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
    Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
    Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
    Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
    Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
    Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
    J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
    Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
    Front Immunol; 2022; 13():991091. PubMed ID: 36248841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Value of
    Chen XJ; Ren AQ; Zheng L; Zheng ED
    Front Immunol; 2021; 12():664847. PubMed ID: 33953726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.
    Hu X; Guo J; Shi J; Li D; Li X; Zhao W
    BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
    Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
    Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
    Li H; Li J; Zhang C; Zhang C; Wang H
    Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.